Dr. Spencer is the Dean and Chief Academic Officer of the PCOM School of Pharmacy at Georgia Campus - Philadelphia College of Osteopathic Medicine. He is originally from New York City and received his pharmacy training with a Bachelor of Science in Pharmacy from Temple University School of Pharmacy in Philadelphia in 1994, where he was inducted into their Gallery of Success. Dr. Spencer was a staff pharmacist at Crozer Keystone Delaware County Memorial Hospital and a pharmacy manager at Eckerd drugs, both in the Philadelphia area. After working in community and hospital pharmacy settings he received his Ph.D. in Pharmaceutical Sciences in 2004, with a research focus on kinetics and thermodynamics of drug-protein binding interactions.
Dr. Spencer served on the faculty of Florida A&M College of Pharmacy where he received an NIH grant studying mechanisms of inhibiting HHV-6 and also received the Class of 2008 Teacher of the Year award. He has held leadership positions in academia as Founding Director of Pharmaceutical Sciences at Fairleigh Dickinson University School of Pharmacy and in research as a Group Leader of Clinical Pharmacology with the National Cancer Institute in Maryland. Before joining PCOM School of Pharmacy, he served as Associate Dean of Institutional Improvement at Florida A&M College of Pharmacy where he launched a NIH-funded Center for Research Education and Training Enhancement and received a Dean’s Appreciation Award in 2015.
Dr. Spencer provides expert testimony and consulting in clinical pharmacology and his research interests include the development of quantitative models relating drug chemistry to bodily absorption. He lives in the city of Atlanta where his hobbies are cycling, reading, swimming and engaging students in discussions on how pharmacists are helping to change healthcare.
Ph.D., Pharmaceutical Sciences, Temple University, Philadelphia, PA
B.S., Pharmacy, Temple University, Philadelphia, PA
Clinical Pharmacology, Biopharmaceutics, Pharmacometrics
Backman JD, O'Connell JR, Tanner K, Peer CJ, Figg WD, Spencer SD, Mitchell BD, Shuldiner AR, Yerges-Armstrong LM, Horenstein RB, Lewis JP. Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response. Pharmacogenet Genomics. 2017 Apr;27(4):159-163.
Andey T, Patel A, Marepally S, Chougule M, Spencer SD, Rishi AK, Singh M. Formulation, Pharmacokinetic, and Efficacy Studies of Mannosylated Self-Emulsifying Solid Dispersions of Noscapine. PLoS One. 2016 Jan 12;11(1).
Udofot O, Jaruszewski K, Spencer S, Agyare E. Development of a novel approach to enhance the solubility of ftibamzone formulation. Integr Mol Med. 2014;1(3):61-66.
Shawn D. Spencer, Lee S. Rosen, Michael S. Gordon, Francisco Robert, Daniela Matei, Cody J. Peer, Bonne Adams, Delia Alvarez, Ben K. Seon, Charles P. Theuer, W. Douglas Figg. Differences in pharmacokinetics of TRC105 (anti-endoglin antibody) when administered as a single agent versus in combination with bevacizumab (Bev). Cancer Res. April 15 2014; 74(8-suppl)
Lewis J, Stephens S, Horenstein R, O'Connell J, Ryan K, Peer C, Figg W, Spencer S, Pacanowski M, Mitchell B, Shuldiner A. The CYP2C19*17 Variant is not Independently Associated with Clopidogrel Response. J Thromb Haemost. 2013 Sep;11(9):1640-6. PMID: 23809542.
Kelly RJ, Thomas A, Rajan A, Chun G, Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, Poondru S, Van Sant C, Keating A, Steinberg SM, Figg W, Giaccone G. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013 Oct;24(10):2601-6. PMID: 23857959.
Figg WD, Chau CH, Madan RA, Gulley JL, Gao R, Sissung TM, Spencer S, Beatson M, Aragon-Ching J, Steinberg SM, Dahut WL. Phase II Study of Satraplatin and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity. Clin Genitourin Cancer. 2013 Sep;11(3):229-37. PMID: 23684781
Peer CJ, Brown JL, Martin TJ, Roth J, Spencer SD, Brassil P, McNeill KA, Kreisl TN, Fine HA, Figg WD. A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Dec 30;942-943:107-12. PMID: 24239935;
Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD. Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int. 2013 Jun;111(8):1269-80. PMID: 23419134
Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, Albert PS, Figg WD, Spencer SD, Raffeld M, Decker JR, Goldman CK, Bryant BR, Petrus MN, Creekmore SP, Morris JC. Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood. 2013 Jan 17; 121(3):476-84. PMID: 23212516.
Peer CJ, Rao M, Spencer SD, Shahbazi S, Steeg PS, Schrump DS, Figg WD. A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 May 15;927:142-6; PMID: 23352636.
Lewis JP, Horenstein RB, Ryan K, O'Connell JR, Gibson Q, Mitchell BD, Tanner K, Chai S, Bliden KP, Tantry US, Peer CJ, Figg WD, Spencer SD, Pacanowski MA, Gurbel PA, Shuldiner AR. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics. 2013 Jan;23(1):1-8.PMID: 23111421.
Gao R, Reece KM, Sissung T, Fu SH, Venzon DJ, Reed E, Spencer SD, Price DK, Figg WD. Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N? BMJ Open. 2013;3(1)PMID: 23293248.
Gordon MS, Rosen LS, Mendelson D, Ramanathan RK, Goldman J, Liu L, Xu Y, Gerson SL, Anthony SP, Figg WD, Spencer S, Adams BJ, Theuer CP, Leigh BR, Weiss GJ. A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. Invest New Drugs. 2013 Jun;31(3):714-23. PMID: 23054206.
Baird, K; Booher, S; Comis, L; Joe, G; Steinberg, SM; Figg, WD; Spencer, SD; Takebe, N; Pavletic, S; Cowen, EW. Imatinib mesylate for the treatment of sclerotic skin chronic graft-versus-host disease. J Invest Dermatol. – May 2012 132, suppl 88
Shawn D. Spencer, William D. Figg, Lee S. Rosen, Michael S. Gordon, Herbert Hurwitz, Michael K.K. Wong, Jonathan Wade Goldman, David S. Mendelson, Bonne J. Adams, Delia Alvarez, Ben K. Seon, Charles P. Theuer, Bryan R. Leigh: Dose-specific clearance of TRC105 (anti-CD105 Antibody) in advanced solid tumor patients. J Clin Oncol 30, 2012 suppl 3042
Baird, K; Booher, S; Comis, LE; Joe, GO; Steinberg, SM; Spencer, SD; Figg, WD; Takebe, N; Pavletic, SZ; Cowen, EW. Phase II Pilot Study of Imatinib Mesylate for the Treatment of Severe Sclerotic Skin Chronic Graft Versus Host Disease (ScGVHD). Biol Blood Marrow Transplant Feb 2012 vol. 18 no. 2 suppl 208
William D Figg, Shawn D Spencer, Steve T Pisle, Heather M Pressler, Sarah M Troutman, Joel R Eisner, Stephen W Rafferty, Robert J Schotzinger, William R Moore. Activity of oral VT-464, a selective CYP17-lyase inhibitor in the LNCaP prostate cancer xenograft. J Clin Oncol 30, 2012 suppl 4671
Sissung TM, Reece KM, Spencer S, Figg WD. Contribution of the OATP1B subfamily to cancer biology and treatment. Clin Pharmacol Ther. 2012 Nov;92(5):658-60. PMID: 23010650.
Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res. 2012 Sep 1;18(17):4820-9. PMID: 22767667;
Spencer S, Marini BL, Figg WD. Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer. Anticancer Res. 2012 Jul;32(7):2391-8. PMID: 22753695.
Patel AR, Spencer SD, Chougule MB, Safe S, Singh M. Pharmacokinetic evaluation and in vitro-in vivo correlation (IVIVC) of novel methylene-substituted 3,3' diindolylmethane (DIM). Eur J Pharm Sci. 2012 May 12;46(1-2):8-16. PMID: 22342559.
Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD, Giaccone G. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res. 2012 Apr 15;18(8):2344-51. PMID: 22371451.
Peng F, Tao Q, Wu X, Dou H, Spencer S, Mang C, Xu L, Sun L, Zhao Y, Li H, Zeng S, Liu G, Hao X. Cytotoxic, cytoprotective and antioxidant effects of isolated phenolic compounds from fresh ginger. Fitoterapia. 2012 Apr;83(3):568-85. PMID: 22248534.
Chen X, Peer CJ, Alfaro R, Tian T, Spencer SD, Figg WD. Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization. J Pharm Biomed Anal. 2012 Mar 25;62:140-8. PMID: 22305081
Troutman SM, Sissung TM, Cropp CD, Venzon DJ, Spencer SD, Adesunloye BA, Huang X, Karzai FH, Price DK, Figg WD. Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis. Oncologist. 2012;17(3):312-20. PMID: 22382457
Peer CJ, Spencer SD, VanDenBerg DA, Pacanowski MA, Horenstein RB, Figg WD. A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jan 1;880(1):132-9. PMID: 22169056;
Wang XY, He ZC, Song LY, Spencer S, Yang LX, Peng F, Liu GM, Hu MH, Li HB, Wu XM, Zeng S, Hilgenfeld R, Stöckigt J, Zhao Y, Qian JF. Chemotherapeutic effects of bioassay-guided extracts of the American cockroach, Periplaneta americana. Integr Cancer Ther. 2011 Sep;10(3):NP12-23. PMID: 21733985.
Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, Figg WD, Chen X, Turkbey IB, Choyke P, Murgo AJ, Doroshow JH, Melillo G. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. Clin Cancer Res. 2011 Aug 1;17(15):5123-31. PMID: 21673063
Li H, Qiang F, Yang Z, Spencer SD, Cui X, Wu X, Chen X. Hepatitis B virus with pre-S2 deletion is more prevalent in hepatocellular carcinoma than in chronic active hepatitis and asymptomatic carriers. Acta Virol. 2011;55(2):183-5. PMID: 21692570.
Billups J, Jones C, Jackson TL, Ablordeppey SY, Spencer SD. Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. Biomed Chromatogr. 2010 Jul;24(7):699-705. PMID: 19908205
Yang LX, Huang KX, Li HB, Gong JX, Wang F, Feng YB, Tao QF, Wu YH, Li XK, Wu XM, Zeng S, Spencer S, Zhao Y, Qu J. Design, synthesis, and examination of neuron protective properties of alkenylated and amidated dehydro-silybin derivatives. J Med Chem. 2009 Dec 10;52(23):7732-52. PMID: 19673490.
Spencer SD, Raffa RB. Isothermal titration calorimetric study of RNase-A kinetics (cCMP --> 3'-CMP) involving end-product inhibition. Pharm Res. 2004 Sep;21(9):1642-7. PMID: 15497691.
Raffa RB, Stagliano GW, Spencer SD. Protonation effect on drug affinity. Eur J Pharmacol. 2004 Jan 12;483(2-3):323-4. PMID: 14729124.
Raffa RB, Spencer SD, Schulingkamp RJ. Toward RNase inhibitors: thermodynamics of 2'-CMP/RNase-A binding in multi-ion buffer. Biochem Pharmacol. 2002 Jun 1;63(11):1937-9. PMID: 12093469.
Spencer SD, Abdul O, Schulingkamp RJ, Raffa RB. Toward the design of ribonuclease (RNase) inhibitors: ion effects on the thermodynamics of binding of 2'-CMP to RNase A. J Pharmacol Exp Ther. 2002 Jun;301(3):925-9. PMID: 12023520.
American Association of Colleges of Pharmacy (AACP)
American Pharmacists Association (APHA)
Georgia Society of Health-System Pharmacists (GSHP)
Georgia Pharmacy Association (GPHA)